BPC 157's demonstrated anti-inflammatory, cytoprotective, and endothelial-protective properties across animal models suggest potential as a complementary treatment for COVID-19's vascular and multi-organ damage.
Multi-organ vascular protectionBPC 157's demonstrated eNOS activation and endothelial protection across organ systems in animal models
What the researchers found
BPC 157's demonstrated eNOS activation, NO-mediated tissue repair, and angiomodulatory properties in animal models provide a theoretical basis for its use as a complementary treatment for COVID-19's endothelial and multi-organ damage.
Why it matters
COVID-19 caused millions of deaths partly through vascular damage and multi-organ failure. Identifying agents that protect the vascular endothelium could improve outcomes and provide treatment options for the vascular complications of this and future pandemic viruses.
The numbers in context
eNOS activation; NO release; endothelial protection; anti-inflammatory; cytoprotective; all from animal models
How the study worked
Medical hypothesis paper reviewing existing animal model evidence for BPC 157's vascular and organ protective effects, applied to COVID-19 pathophysiology.
Who was studied
Hypothesis paper reviewing BPC 157 animal data in context of COVID-19
What this study cannot tell us
Hypothesis paper based on animal model data — no human COVID-19 clinical trial data. BPC 157 lacks FDA approval and comprehensive human safety data. Theoretical extrapolation from other conditions to COVID-19.
How to read the evidence
Medical hypothesis based on animal model evidence extrapolated to COVID-19. No clinical trial data available for this specific application.
When this study was published
Published in 2021 during the COVID-19 pandemic, proposing a novel therapeutic approach based on existing animal research.
The bigger picture
BPC 157 has been extensively studied for its healing and protective properties across many organ systems. Applying its known vascular protective mechanisms to COVID-19 pathology represents a logical extension of its documented effects, though human clinical data remains the critical missing piece.
Questions still open
- Would BPC 157 be effective in human COVID-19 patients?
- What dose and timing would be optimal for COVID-19 vascular protection?
- Could BPC 157 prevent long COVID vascular complications?
Common questions
Could BPC 157 help with COVID-19?
Is BPC 157 approved for treating COVID-19?
Read the original research
BPC 157 as Potential Treatment for COVID-19.
Medical hypotheses, 158, 110736
Citation
Deek, Sarah A. (2021). BPC 157 as Potential Treatment for COVID-19.. Medical hypotheses, 158, 110736. https://doi.org/10.1016/j.mehy.2021.110736